ir.compasspathways.com/News--Events...

This collaboration combines Osmind's deep understanding of how clinics operate with Compass's scientific expertise to inform scalable, real-world pathways for the potential delivery of novel psychedelic treatments in mental health care.

Learn more in the full press release:

Independent practices are where most patients receive their care, but they've historically been left behind when it comes to adopting novel treatments.

Osmind is proud to collaborate with Compass Pathways to help independent psychiatry practices prepare for the potential future delivery of psychedelic medicine.

This is the work we've been doing at Osmind for the last six years, alongside the 1,000+ independent psychiatry practices we serve navigating this every day. We're glad it's becoming a national priority.

It's also where real-world evidence becomes critical. The EO specifically calls for RWE generation, and the reason is simple: clinical trials tell you what a treatment can do. Real-world data tells you how it works across the actual patient populations and practice settings where care is delivered.

Between federal approval and a patient receiving treatment at an independent practice, there's an operational gap that policy alone can't close. REMS compliance, drug procurement, EHR documentation standards, reimbursement, staff training: practices are largely left to figure this out on their own.

Saturday's executive order clears federal roadblocks that have slowed psychedelic treatments for decades. But approval (if and when it comes) doesn't equal access.

www.osmind.org/blog/carenet...

Osmind partnered with CareNet GPO.

Through this partnership, practices get negotiated savings on specialty medications starting with Spravato®, a community of peers sharing what works across buy-and-bill, inventory management, and operations, and resources to help your practice grow sustainably.

Treatment Resistant Depression, Residual Symptoms, and Remission | Psychiatric Times Experts unpack why depression persists after multiple meds, how to spot true treatment resistance, and strategies to achieve full remission.

www.psychiatrictimes.com/view/treatme...

Treatment-resistant depression doesn't have a formal DSM definition. But most psychiatrists know it when they see it—and most of them are seeing it constantly.

Watch: Psychiatric Times panel to see why depression persists after multiple medication trials, and what full remission actually requires.

GLP-1 Agonists Are Psychiatric Drugs. Psychiatry Should Start Acting Like It | Osmind Are GLP-1 agonists psychiatric drugs? The neuroscience of reward, new addiction trial data, and a dosing hypothesis that reframes anhedonia.

Eli Lilly just launched Phase 3 trials for a GLP-1 drug in alcohol use disorder. Not diabetes. Not weight loss. Addiction.

What psychiatrists need to know:

www.osmind.org/blog/glp-1-p...

How SPRAVATO® (esketamine) Helped Ben Finally See Himself Clearly | Osmind Hear how one Spravato patient went from cycling through 10 antidepressants to building a life he loves — running marathons, writing novels, and surfing. Ben Leopold shares how the combination of deep ...

Five years ago, Benjamin Leopold was curled on his apartment floor with a bottle of scotch. Today he runs marathons, writes horror novels, and surfs whenever he can get to the coast.

SPRAVATO® (esketamine) gave a bird’s eye view to years of trauma.

www.osmind.org/blog/spravat...

Guide to Adding TMS to Your Psychiatric Practice | Osmind Ready to add TMS to your practice? This guide covers patient eligibility, 2026 device pricing for 8 systems, financing, billing codes, and how to build your referral pipeline from day one.

For psychiatrists looking to help treatment-resistant patients while adding a profitable service line, TMS is worth a serious look.

www.osmind.org/blog/guide-t...

Osmind Psychiatry Collective Login to Osmind Psychiatry Collective community via email or SSO today.

Both sessions will be recorded for members who can't attend live.

RSVP for upcoming events: community.osmind.org/c/events/

Not a member yet? Join free: www.osmind.org/join-communi...

🔬 GLP-1s in Psychiatry

Thu, Feb 12 | 11:00 AM – 12:00 PM PST GLP-1s in Psychiatry with Annette Bosworth, hosted by Dr. Will Sauvé

⚡ TMS Best Practices & Training

Wed, Feb 18 | 9:00 – 9:30 AM PST with Ben Spielberg, PhD (Solstice Training Institute), hosted by Dr. Will Sauvé

our patients started a GLP-1 for weight loss. Then they stopped drinking. Then they quit smoking. Then the compulsive shopping slowed down.

Sound familiar? You're not alone. This is just one of the conversations happening right now inside the Psychiatry Collective.

Link to register in the comments.
See Indications and Important Safety:www.livanova.com/.../healthcare-provider-...

Stay tuned for more from this collaboration and join us on February 19 for a deep dive into published clinical research behind VNS Therapy™, featuring findings from the RECOVER trial.

This represents our shared mission of advancing mental healthcare and the emerging field of Interventional Psychiatry.

Osmind is excited to partner with LivaNova to support education and awareness for clinicians caring for people living with difficult-to-treat depression (DTD).

SPRAVATO J Code: What Clinicians Need to Know | Osmind CMS replaced S0013 with the new Spravato J code (J0013) in 2026, but payer rollouts have been inconsistent. Learn which prior authorizations need to be redone and how to protect your practice from cla...

One clinician saw their Spravato reimbursement drop $90 overnight in January. The culprit? A billing code change nobody warned them about.

CMS replaced S0013 with J0013 in 2026. Same drug. Same unit. New code. But the rollout has been messy: www.osmind.org/blog/spravat...

Thank you to everyone who stopped by, shared your stories, and reminded us why we do this work. The future of interventional treatment is bright, and it's being built by clinicians like you.

See you next year! American Society of Ketamine Physicians, Psychotherapists and Practitioners

•Osmind Scientific Advisor L. Alison McInnes MD, MS. presented real-world data on ketamine for PTSD from 1,340 patients across our network.

• Compliance questions are changing. Less "can I do this?" and more "how do I do this right?" Clinicians want to offer innovative treatments confidently—and they're looking for partners who understand the regulatory landscape.

• The conversation has shifted. Clinicians aren't just talking about ketamine anymore—they're asking how to add TMS, Spravato, and accept insurance to build sustainable, long-term practices. The next evolution of interventional psychiatry is here.

Just wrapped ASKP3 and feeling energized. Some highlights from the conference:

Does inflammation cause depression?

This year, Osmind Scientific Advisor L. Alison McInnes MD, MS. takes the main stage to present real-world data on ketamine for PTSD from 1,340 patients across our network.